[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nec\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nec":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,50,77,107,134,158,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100488152","safety-and-pk-pd-study-of-oral-l-cit-in-preterm-infants-with-bpdph-and-nec-100488152",false,"NCT05636397","Safety and PK-PD Study of Oral L-CIT in Preterm Infants With BPD±PH and NEC","A Phase I, Safety and Pharmacokinetics\u002FPharmacodynamics Study of Oral L-CIT Supplementation in Preterm Infants With BPD±PH and NEC","Arm 1: BPD±PH:\n\nInclusion Criteria:\n\n* Born ≤ 30 weeks at birth\n* Post-menstrual age (PMA) ≥ 32 weeks\n* Echocardiographic evidence of PH for infants with BPD+PH.\n* On invasive or non-invasive ventilation with RSS \\>2.0 for \\>12hours\u002Fday for at least 48 hours as an early predictor of evolving BPD\n* Informed written consent (parents\u002Fsubstitute decision maker)\n\nExclusion Criteria\n\n* Congenital Heart Disease \\[Exceptions: small atrial septal defect (ASD), small ventricular septal defect (VSD), small patent ductus arteriosus (PDA)\\]\n* Infants with pulmonary vein stenosis\n* Concurrent sepsis with hemodynamic instability\n* Infants considered likely to die within next 7 days\n* Any other condition that, in the opinion of the investigator, may adversely affect the infant's ability to complete the study or its measures or pose significant risk to the infant\n\nArm 2: surgical NEC\n\nInclusion Criteria:\n\n* Born ≤ 30 weeks at birth\n* Recovering from Stage IIIb NEC as per modified Bell's staging (pneumoperitoneum requiring surgery)\n* Tolerating 50 ml\u002Fkg\u002Fday of enteral feeds\n* Informed written consent (parents\u002Fsubstitute decision maker)\n* Considered medically stable by clinical team\n\nExclusion Criteria\n\n* Congenital heart disease (except small ASD, small VSD and non hsPDA)\n* Pulmonary vein stenosis\n* Concurrent sepsis with hemodynamic instability\n* Likely to die within next 7 days\n* Other condition significantly affecting pulmonary function independent of prematurity or NEC","ALL","1 Month","6 Months",{"count":20,"type":21},36,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to evaluate the safety and explore the PK\u002FPD of L-CIT supplementation in preterm infants to prevent the development of inflammatory pathways initiated by low levels of plasma CIT, specifically in preterm infants with post-surgical NEC and BPD±PH.",[27,28,29],"BPD - Bronchopulmonary Dysplasia","Pulmonary Hypertension","NEC",[31,32,33,34,35,36],"BPD±PH","surgical NEC","L-Citrulline","Pharmacokinetic profile","Pharmacodynamic profile","Preterm neonates","RECRUITING","2026-04-28",{"date":40,"type":41},"2026-05-04","ACTUAL",{"date":43,"type":41},"2023-11-01",{"date":45,"type":21},"2028-03",{"name":47,"class":48},"The Hospital for Sick Children","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":76},"100624981","phase-1-a-phase-i-clinical-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-hlx3901-in-patients-with-advanced-sclc-or-nec-100624981","NCT07416695","A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC","A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 (DLL3 × DLL3 × CD3 × CD28 Tetra-specific Antibody) in Patients With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma","Inclusion Criteria:\n\n1. Have a full understanding of the study content, process, and possible adverse reactions before the study, and sign the informed consent form (ICF); voluntarily participate in the study; be able to complete the study as per protocol requirements;\n2. Aged ≥ 18 years and ≤ 75 years at the time of signing the ICF, male or female;\n3. Histologically or cytologically confirmed advanced small cell lung cancer or neuroendocrine carcinoma; patients with advanced small cell lung cancer must have experienced intolerance, recurrence, or disease progression following prior treatment with a platinum-based therapy combined with immune checkpoint inhibitors, while patients with neuroendocrine carcinoma must have experienced intolerance, recurrence, or disease progression following prior platinum-based therapy; allowed histological subtypes include combined small cell lung cancer and mixed neuroendocrine-non-neuroendocrine neoplasms.\n4. At least one measurable lesion as per RECIST 1.1 within 4 weeks prior to the first administration;\n5. An ECOG performance status score of 0-1 within 7 days prior to the first administration;\n6. Expected survival \\> 3 months;\n7. The following conditions must be met in terms of the time of the first administration of the investigational product: at least 28 days from the previous major surgery, medical device treatment, locoregional radiotherapy (except for palliative radiotherapy for bone lesions), cytotoxic chemotherapy, immunotherapy, or biological product therapy; at least 14 days from the previous small molecule targeted drug therapy and previous hormone therapy; at least 7 days from the previous administration of the traditional Chinese medicine for anti-tumor indications or minor surgery; recovery of treatment-induced AEs to Grade ≤ 1 (CTCAE v6.0, except for alopecia);\n8. Participants who agree to provide archived tumor tissue specimens that meet the testing requirements (either from the most recent surgery or biopsy, preferably within 2 years) or agree to undergo a biopsy to collect tumor tissue for DLL3 expression testing; Note: Formalin-fixed paraffin-embedded (FFPE) tumor samples (paraffin blocks or unstained sections, which must meet the quality control criteria for testing) collected from non-radiotherapy sites during the most recent surgery or biopsy at or after the diagnosis of malignant tumor and pathological reports of such specimens shall also be provided.\n9. Adequate organ function as confirmed by laboratory tests within 7 days prior to the first administration of the investigational product, with no therapies such as blood transfusion, albumin infusion, renal replacement therapy, granulocyte colony-stimulating factor (G-CSF), thrombopoietin, or erythropoietin administered within 14 days prior to the first administration:\n10. Male and female participants with child-bearing potential must agree to use at least one highly effective contraception method during the study and within at least 6 months after the last dose of the investigational product; female participants of childbearing age must be negative for pregnancy test within 7 days prior to enrollment.\n\nExclusion Criteria:\n\n1. History of other malignant tumors within 2 years prior to the first administration, except cured cervical carcinoma in situ or cutaneous basal cell carcinoma;\n2. Presence of Grade ≥ 2 immune-related pneumonitis or immune-related myocarditis, or severe, life-threatening immune-mediated AEs or infusion-related reactions, including those leading to permanent discontinuation, when receiving previous anti-tumor immunotherapy;\n3. History or presence of clinically significant pulmonary impairment due to concurrent lung disease, including but not limited to any underlying lung disease (e.g., pulmonary embolism within 3 months prior to the first administration, severe asthma, severe chronic obstructive pulmonary disease, restrictive pulmonary disease, interstitial pneumonia, pneumoconiosis, drug-related pneumonitis, and pleural effusion), any autoimmune, connective tissue, or inflammatory disease that may involve the lungs (i.e., rheumatoid arthritis, Sicca syndrome, and sarcoidosis), prior pneumonectomy that may interfere with the detection and management of suspected drug-related pulmonary toxicity, or history of radiation pneumonitis within the past 6 months;\n4. With central nervous system diseases within 12 months prior to enrollment, such as seizures, cerebral hemorrhage, paralysis, aphasia, cerebral infarction (except for old cerebral infarction), severe brain injury, dementia, Parkinson's disease, cerebellar disease, mental illness, or any autoimmune disease involving the central nervous system;\n5. Active paraneoplastic syndrome;\n6. History of hypophysitis or pituitary dysfunction;\n7. Presence of uncontrolled third-space effusions (e.g., massive pleural effusion, ascites, or pericardial effusion) requiring repeated drainage and considered by the investigator to be unsuitable for enrollment;\n8. Prior allogeneic stem cell or solid organ transplantation;\n9. Prior exposure to any of the following: (1) combination or sequential therapy targeting DLL3, CD3, or CD28; (2) treatment with antibody-drug conjugates (ADCs); (3) major surgery, chemotherapy, biologic therapy, endocrine therapy, or macromolecular targeted therapy within 4 weeks prior to the first administration. Traditional Chinese medicine and small molecule targeted therapy with anti-tumor indications ≤ 2 weeks from the first administration of the investigational product;\n10. Known history of severe allergic reactions, anaphylactoid reactions, or other hypersensitivity reactions to humanized antibodies or fusion proteins, severe allergic reactions to macromolecular protein preparations\u002Fmonoclonal antibodies, or allergy to components of the investigational product preparations;\n11. Active systemic infectious diseases requiring intravenous antibiotics within 2 weeks prior to the first administration of the investigational product;\n12. Any poorly-controlled cardiovascular and cerebrovascular clinical symptoms or diseases, including but not limited to: (1) NYHA Class II or greater heart failure or left ventricular ejection fraction (LVEF) \\\u003C 50%; (2) unstable angina pectoris; (3) myocardial infarction or cerebrovascular accident within 6 months (except lacunar infarction, slight cerebral ischemia, or transient ischemic attack); (4) poorly controlled arrhythmia (including QTc intervals ≥ 450 ms for males and ≥ 470 ms for females) (QTc intervals are calculated by Fridericia's formula); (5) poorly-controlled hypertension (systolic blood pressure \\> 150 mmHg and\u002For diastolic blood pressure \\> 100 mmHg after active treatment);\n13. Active central nervous system (CNS) metastases and\u002For carcinomatous meningitis known or diagnosed at screening. However, the following participants are allowed to be enrolled: 1) Patients with asymptomatic brain metastases (i.e., no progressive central nervous system symptoms caused by brain metastases, no requirement for corticosteroids, and lesion size ≤ 1.5 cm) may be included, but are required to receive regular brain imaging as a site of disease. 2) Participants with treated brain metastases that have been stable for at least 2 months (confirmed by 2 imaging assessments at least 4 weeks apart following brain metastasis treatment), with no evidence of new or enlarging brain metastases and discontinued steroids at least 3 days prior to administration (stable brain metastases here should be confirmed before the first administration of the investigational product).\n14. Patients with known active or suspected autoimmune diseases. Patients with autoimmune-related hypothyroidism who are receiving thyroid hormone replacement therapy and those with type 1 diabetes mellitus controlled with insulin therapy are eligible to be enrolled;\n15. Patients who have received systemic corticosteroids (prednisone \\> 10 mg\u002Fday or equivalent dose of a similar drug) or other immunosuppressive agents within 14 days prior to the first administration; Except: patients treated with topical, ocular, intra-articular, intranasal, and inhaled corticosteroids; those with short-term use of corticosteroids for prophylaxis if a contrast agent is used;\n16. Patients with active tuberculosis;\n17. Patients with a history of immunodeficiency, including human immunodeficiency virus (HIV)-positive or other acquired or congenital immunodeficiencies, or a history of organ transplantation;\n18. Patients with active HBV or HCV infection or HBV\u002FHCV co-infection; Note: Patients who are HBsAg (+) and\u002For HBcAb (+) must undergo an HBV-DNA test and have a result \\\u003C 500 IU\u002FmL, \\\u003C 2500 copies\u002FmL, or \\\u003C ULN to be enrolled. Enrolled participants with detectable HBV-DNA must consent to receive antiviral nucleoside\u002Fnucleotide therapy.\n\n    If HCV antibody (+), HCV-RNA must be tested, and the result must be \\\u003C ULN for the participant to be eligible.\n\n    Participants with HBV\u002FHCV co-infection shall be excluded (positive for HBsAg or HBcAb and positive for HCV antibody).\n19. Have received live vaccines within 28 days prior to the first administration;\n20. Pregnant or lactating women;\n21. Participants who are not suitable for participating in this clinical study due to any clinical or laboratory abnormalities or other reasons as assessed by the investigator.","18 Years","75 Years",{"count":60,"type":21},138,[62],"PHASE1","This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3901 in patients with Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma.",[65,29],"SCLC","2026-04-23",{"date":68,"type":41},"2026-04-29",{"date":70,"type":41},"2026-04-17",{"date":72,"type":21},"2029-06-30",{"name":74,"class":75},"Shanghai Henlius Biotech","INDUSTRY",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":49},"100607678","mechanisms-affecting-the-gut-of-preterm-infants-receiving-blood-transfusion-with-different-enteral-feed-interventions-100607678","NCT07191678","Mechanisms Affecting the Gut of Preterm Infants Receiving Blood Transfusion With Different Enteral Feed Interventions","MAGPIE-2","Inclusion Criteria:\n\n* Very preterm babies (born between 23 to \\\u003C30 weeks of gestational age ) in the WHEAT International trial\n* Written informed consent from parents\n\nExclusion Criteria:\n\n* Babies who are deemed too unstable to perform the non-invasive monitoring and the ultrasound scan measurements by the attending clinical team\n* Babies who have already developed Bells stage 2 NEC, had bowel surgery or congenital abdominal conditions such as congenital diaphragmatic hernia, gastroschisis and exomphalos","23 Weeks","30 Weeks",{"count":87,"type":21},270,"OBSERVATIONAL","MAGPIE-2 is a prospective observational study designed to investigate the physiological mechanisms linking blood transfusion and enteral feeding practices to gut perfusion and oxygenation in very preterm infants. The study is nested within the WHEAT International randomised controlled trial, which compares two standard care approaches: withholding versus continuing milk feeds during red blood cell transfusion. While WHEAT evaluates clinical outcomes such as necrotising enterocolitis (NEC), MAGPIE-2 focuses on the underlying physiological changes that may contribute to NEC development.\n\nNEC is a serious gastrointestinal condition affecting approximately 10% of extremely preterm infants and is associated with high mortality and long-term neurodevelopmental impairment. Previous observational studies have suggested a temporal link between blood transfusion and NEC onset, particularly when feeds are continued during transfusion. However, the mechanisms remain poorly understood.\n\nMAGPIE-2 will use non-invasive monitoring tools-near-infrared spectroscopy (NIRS) and Doppler ultrasound-to measure cerebral and splanchnic (gut) tissue oxygenation and superior mesenteric artery (SMA) blood flow. These measurements will be used to calculate the Splanchnic-Cerebral Oxygenation Ratio (SCOR), a validated marker of gut tissue perfusion and ischaemia. A reduction in SCOR may indicate compromised gut oxygenation, potentially contributing to NEC.\n\nThe study will recruit 270 infants (135 per arm) already enrolled in the WHEAT trial. Weekly measurements will be taken until 34 weeks corrected gestational age or discharge. Peri-transfusion monitoring includes continuous NIRS from 4 hours before to 4 hours after transfusion, and additional 2-hour recordings at approximately 24 and 48 hours post-transfusion. SMA Doppler assessments will be performed weekly.\n\nPrimary outcomes include changes in SCOR post-transfusion between the two feeding strategies. Secondary outcomes include changes in cerebral and splanchnic oxygenation, SMA blood flow velocities, and the impact of severe anaemia (pre-transfusion haemoglobin ≤80 g\u002FL) on these parameters. The study also includes an assessment of inter-operator variability in Doppler measurements.\n\nMAGPIE-2 aims to provide mechanistic insights that could inform safer transfusion and feeding practices in neonatal care, potentially reducing the incidence of NEC in this vulnerable population.",[91,29,92,93],"NEC - Necrotizing Enterocolitis","Preterm Babies","Preterm Infant Health",[29,95,96,97],"Necrotizing Enterocolitis","Necrotising Enterocolitis","Preterm","2026-03-26",{"date":100,"type":41},"2026-04-01",{"date":102,"type":41},"2025-11-03",{"date":104,"type":21},"2027-04-30",{"name":106,"class":48},"Imperial College Healthcare NHS Trust",{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":49},"100568431","study-of-normal-intestinal-development-and-disease-in-premature-and-term-neonates-100568431","NCT06681129","Study of Normal Intestinal Development and Disease in Premature and Term Neonates","Study of Normal Intestinal Development and Disease in Premature and Term Neonates - a Pathway for the Study of Premature and Neonatal Intestinal Disorders Including the Roles of Nutrition, Microbes, and Cellular Physiology, and Diseases Including Necrotizing Enterocolitis","NiiCE","Inclusion Criteria:\n\n* Any neonate or infant through 2 years of age having intestinal surgery or intestinal biopsies from an esophogastroduodenoscopy (EGD) or colonoscopy.\n\nExclusion Criteria:\n\n* Children \\> 2 years of age.\n* Infants 0-2 years old not undergoing GI surgery or intestinal scope with biopsy procedure.","2 Years",{"count":117,"type":21},100,"Current research on early intestinal development is primarily performed in mouse models. While useful in many other ways, mouse models are not ideal for studying human intestine development as the timing of this process differs between the two species. Further, prior research has demonstrated that some proteins and pathways that are critical in human development have no clear role in mice.\n\nThis study aims to improve the overall understanding of critical aspects of intestinal development in humans. In addition, this study will investigate the impact of intestinal diseases that are found in the early stages of life such as necrotizing enterocolitis (NEC).",[29,95,120,121],"Intestinal Disease","Human Development",[29,123,124,95],"Early Intestinal Development","Intestinal Intervention","2026-03-24",{"date":127,"type":41},"2026-03-27",{"date":129,"type":41},"2025-03-17",{"date":131,"type":21},"2034-12-31",{"name":133,"class":48},"Boston Children's Hospital",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":140,"sex":16,"minAge":4,"maxAge":141,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":4},"100610884","assessing-the-efficacy-of-probiotics-in-prevention-of-nec-in-preterm-babies-100610884","NCT07233382","Assessing the Efficacy of Probiotics in Prevention of NEC in Preterm Babies","Inclusion Criteria:\n\n* Male and female preterm infants with a gestational age less than 35 weeks.\n* All indoor patients and outdoor patients who present within 24hrs of birth\n\nExclusion Criteria:\n\n* • Infants with congenital or developmental gastrointestinal disorders for example omphalocele, malrotation, gastroschisis.\n\n  * Infants with severe sepsis or gastrointestinal bleeding on presentation",true,"1 Day",{"count":143,"type":21},196,[24],"The goal of the study is to check efficacy of probiotics in preventing necrotizing enterocolitis. The main questions would be if the preterm baby developed NEC or not.",[29,91],"NOT_YET_RECRUITING","2025-11-28",{"date":150,"type":41},"2025-12-05",{"date":152,"type":21},"2025-12-01",{"date":154,"type":21},"2026-05-30",{"name":156,"class":157},"Hayatabad Medical Complex","OTHER_GOV",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":166,"enrollmentInfo":167,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100460639","sensing-oxygen-saturations-using-abdominal-nirs-with-an-investigational-realtime-device-songbird-100460639","NCT05278247","Sensing Oxygen Saturations Using Abdominal NIRS With an Investigational Realtime Device (Songbird)","An Open Single-center Study in England to Assess Safety and Performance of a NIRS System to Monitor Abdominal Tissue Oxygen Saturation in Preterm Infants","(Songbird)","Inclusion Criteria:\n\n1. Preterm infants with Gestational age less than 35 0\u002F7 weeks\n2. Signed Informed consent of the legal representative(s) is received after being informed. The consent form is signed by one legal representative, which is likely to be either the mother or the father. Only married fathers or those listed on the birth certificate are considered under UK regulations. In the case of non-married father, the mother must provide consent.\n3. Clinically stable condition. The clinical stability is to be reconfirmed before the start and checked during the measurement.\n\nExclusion Criteria:\n\n1. Injured, hypersensitive or bruised skin present on the abdomen,\n2. Existence of clinical instability at any time during the investigation leads to exclusion, if ordered so by the physician entrusted with the investigation,\n3. Any medical care equipment, e.g. patches, dressing, umbilical arterial or venous catheter, blood supply, etc., prohibiting correct placement of the sensors,\n4. Severe Congenital malformations,\n5. Clinical abdominal concerns\n6. Severe metabolic disorders,\n7. Early onset sepsis,\n8. Inability of legal representatives to understand the purpose of the clinical trial due to language barriers such as the insufficient ability to understand the spoken or written language,\n9. The treatment of newborn jaundice with light during measurement time phase 1 and 2,\n10. Previous enrolment into the current study,\n11. Family members, employees and other dependent persons of the investigator,\n12. Participation in another study with investigational drug\u002Fdevice within the preceding days and during the present study which may influence abdominal oxygen saturation.\n13. Known silicone allergy","7 Days",{"count":168,"type":21},50,[24],"Preterm infants are highly vulnerable and may suffer from multiple life-threatening conditions that manifest low tissue oxygenation (StO2). Near infrared spectroscopy (NIRS) is a technique available to non-invasively and safely monitor the tissue oxygenation status (StO2), which can be beneficial or live saving for this fragile patient population. Unfortunately, traditional NIRS devices show a broad variability when applied to the abdomen (Bailey \\& Mally 2016). The novel device is designed especially for application of NIRS on the abdomen of preterm infants.",[29],[173],"abdominal NIRS for oxygen saturation","2025-11-24",{"date":148,"type":41},{"date":177,"type":21},"2026-02-01",{"date":179,"type":21},"2027-12-31",{"name":181,"class":75},"Carag AG",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":192,"conditions":193,"keywords":197,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":49},"100583271","non-invasive-prediction-of-necrotizing-enterocolitis-in-preterm-neonates-with-feeding-intolerance-using-fecal-lipocalin-2-and-electrical-cardiometry-100583271","NCT06874153","Non-Invasive Prediction of Necrotizing Enterocolitis in Preterm Neonates with Feeding Intolerance Using Fecal Lipocalin-2 and Electrical Cardiometry","Non-Invasive Prediction of Necrotizing Enterocolitis in Preterm Neonates with Feeding Intolerance","Inclusion Criteria:\n\nPreterm neonates with gestational age ≤ 35 weeks, admitted to NICU, started enteral feeding and diagnosed as having feeding intolerance defined as stage IA and IB by modified bell's staging\n\nExclusion Criteria:\n\n1. Chromosomal anomaly or multiple congenital malformations.\n2. Patient with surgical malformation of the intestinal tract (i.e. omphalocele, gastroschisis, malrotation, intestinal atresia)\n3. Patient diagnosed as hypoxic ischemic encephalopathy.","28 Days",{"count":191,"type":21},42,"Prospective observational study to evaluate the efficiency of using electrical cardiometry in combination with fecal lipocalin-2 for prediction of NEC in preterm neonates with feeding intolerance",[194,29,195,196],"Feeding Intolerance in Preterm","Electrical Cardiometry","PreTerm Neonate",[198,29,195,199,200,201],"preterm","SMA flow","feeding intolerance in preterm","Fecal lipocalin-2","2025-03-08",{"date":204,"type":41},"2025-03-13",{"date":206,"type":21},"2025-03-05",{"date":208,"type":21},"2026-06-05",{"name":210,"class":48},"Ain Shams University"]